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Background: Cholangiocellular carcinoma is the second most common primary liver cancer after hepatocellular
carcinoma. Over the last 30 years, the incidence of intrahepatic cholangiocellular carcinoma has risen continuously
worldwide. Meanwhile, the intrahepatic cholangiocellular carcinoma has become more common than the extrahepatic
growth type and currently accounts for 10-15% of all primary hepatic malignancies. Intrahepatic cholangiocellular
carcinoma is typically diagnosed in advanced stages due to late clinical symptoms and an absence of classic risk
factors. A late diagnosis precludes curative surgical resection. There is evidence that transarterial chemoembolization
leads to better local tumor control and prolongs survival compared to systemic chemotherapy. New data indicates that
selective internal radiotherapy, also referred to as radioembolization, provides promising results for treating intrahepatic
cholangiocellular carcinoma.
Methods/Design: This pilot study is a randomized, controlled, single center, phase II trial. Twenty-four patients with
intrahepatic cholangiocellular carcinoma will be randomized in a 1:1 ratio to receive either chemoembolization or
radioembolization. Randomization will be stratified according to tumor load. Progression-free survival is the primary
endpoint; overall survival and time to progression are secondary endpoints. To evaluate treatment success, patients will
receive contrast enhanced magnetic resonance imaging every 3 months.
Discussion: Currently, chemoembolization is routinely performed in many centers instead of systemic chemotherapy
for treating intrahepatic cholangiocellular carcinoma confined to the liver. Recently, radioembolization has been
increasingly applied to cholangiocellular carcinoma as second line therapy after TACE failure or even as an alternative
first line therapy. Nonetheless, no randomized studies have compared radioembolization and chemoembolization.
Considering all this background information, we recognized a strong need for a randomized controlled trial (RCT) to
compare the two treatments. Therefore, the present protocol describes the design of a RCT that compares SIRT and
TACE as the first line therapy for inoperable CCC confined to the liver.
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Epidemiology
Cholangiocellular carcinoma (CCC) is the second most
common primary liver cancer after hepatocellular car-
cinoma (HCC) [1]. CCCs are classified according to their
location; they are either intrahepatic or extrahepatic hilar
CCCs [2]. Over the last 30 years, the incidence of intra-
hepatic CCC has risen continuously worldwide [3-5]. In
1975 to 1979, the incidence was only 0.32 per 100,000
people; by 1995 to 1999, the incidence had risen to 0.85
per 100,000 people. Moreover, the intrahepatic CCC sub-
type became more common than the extrahepatic subtype
[6]. Currently, the intrahepatic subtype accounts for 10 to
15% of primary hepatic malignancies [7].Diagnosis
Only a few patients present typical risk factors: the ma-
jority of cases develop spontaneously in patients with
non-cirrhotic liver [5,8-18]. There are no early changes
in standard blood parameters. This relative indepen-
dence from classic risk factors, and the lack of jaundice
and early clinical symptoms typically delays diagnosis
[2,19]. Currently, ultrasound is the most frequently per-
formed imaging method [20]. Nonetheless, there are
only a few specific diagnostic criteria for intrahepatic
CCC [21,22], and inter-observer variability is high [23].
Therefore, cross-sectional imaging with computed tomo-
graphy (CT) or magnetic resonance imaging (MRI) is
mandatory.Computed tomography
Contrast-enhanced CT is a widely used method for the
primary diagnosis and staging of CCC [22]. CT allows
evaluation of the primary tumor and can rule out extrahe-
patic metastasis [24]. Typical imaging features are nodular,
irregularly shaped intrahepatic masses, which show mo-
derate contrast enhancement in the arterial and portal
venous phases [22].Magnetic resonance imaging
Due to its high soft-tissue contrast, MRI with an intra-
venous contrast medium is the modality of choice for
staging of intrahepatic CCC [25,26]. In analogy to CT,
the tumor shows only moderate contrast enhancement
in the arterial and portal venous phases and prolonged
enhancement in the late phases [27,28].Prognosis
The prognosis of intrahepatic CCC is poor [5,6,29]. In the
last few decades, a small improvement was observed in
the 1-year survival rate, which rose from 16.4% (1975 to
1979) to 27.6% (1995 to 1999). This improvement was
mainly due to better supportive care. The main reason for
the poor prognosis is the late diagnosis leading to ad-
vanced stages [6]. Prognosis is correlated with the tumor
stage and lymph node status (5-year survival rates for pa-
tients with lymphatic infiltration versus those without
were 44% versus 11%, respectively) [30].
Treatments
Resection
Surgical resection is the treatment of choice [5]. When a
complete removal (R0-resection) is accomplished, 3-year
survival rates of 40 to 60% are reported [31-38]. However,
when the tumor is incompletely removed, the results are
not better than those obtained with palliative care [39].
Local ablative therapy
Patients with very few but clearly definable lesions can be
treated with local ablative therapies like radiofrequency or
microwave ablation. The intention is to completely ablate
the tumor, including a safety margin of a least 1 cm [40].
Because 5 cm of liver tissue is the maximum diameter that
can be safely ablated with the standard probes available,
3 cm is typically the maximum tumor diameter suggested
for ablation.
Chemotherapy
Survival was proven to be higher with Cisplatin and
Gemcitabine compared to Gemcitabine monotherapy
[41]. Nonetheless, only 59% of patients in that study had
extra- or intrahepatic CCC; the remainder had tumors
in papillary tissues and the gallbladder. Therefore, those
results were only partially applicable to patients with
intrahepatic CCC.
Transarterial chemoembolization
Transarterial chemoembolization (TACE) is based on
delivering small particles into the tumor feeding arteries
via a catheter to cause embolization or occlusion of the
tumor’s arterial supply. The particles also contain a che-
motherapeutic agent for specific tumor treatment. In
inoperable patients, survival was greater with TACE than
with best supportive care [42-44]. Recently published
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beads (DEB TACE) lead to better local tumor control and
both prolonged progression-free survival (PFS) and overall
survival (OS) compared to systemic chemotherapy [45].
The rate of side effects was acceptable; thus, TACE was
considered a good method for preserving quality of life for
as long as possible [42,45,46].
The need for a trial
As indicated above, the only curative therapies for intrahe-
patic CCC are surgical resection with tumor-free margins
[39] or local ablative therapy with a sufficient safety margin
[40]. Unfortunately, most patients are initially diagnosed in
an advanced stage, which prohibits a curative approach. In
the palliative setting, no treatment alternatives can provide
satisfactory results. In the advanced stages, with extra-
hepatic spread of the tumor, systemic chemotherapy is the
treatment of choice. When the tumor is still confined to
the liver, TACE can serve as an alternative to systemic
chemotherapy, with lower side effects and a considerably
higher local antitumor effect [44,45,47].
Over the last few years, selective internal radiotherapy
(SIRT) has been increasingly used as a second-line therapy
for HCC treatment in case of TACE failure. Basically, SIRT
is based on the same principles as TACE. The main differ-
ence is that SIRT relies on smaller-sized particles that are
loaded with a radioactive beta emitter leading to an in-
ternal radiation therapy with very high local doses. One of
its main advantages is the reduced number of treatments
needed compared to TACE (1 to 2 versus 4 to 10 treat-
ments) and the enhanced quality of life [48]. Additionally,
repetitive TACE may be associated with considerable vessel
damage. Therefore, SIRT has been increasingly discussed
as a possible first-line therapy option for patients with
CCC confined to the liver. New data has already shown
promising results for patients with intrahepatic CCC
treated with SIRT [49]. The reduced number of treatment
sessions and the smaller size of the particles preserve the
patency of the tumor feeding arteries. Consequently, direct
access to tumor vessels is maintained, which enables the
application of another local treatment (for example, TACE
as a second-line treatment) in case of SIRT failure.
No randomized study has been published on the treat-
ment of CCC with SIRT. Considering all this background
information, we recognized a strong need for a ran-
domized controlled trial (RCT) to compare the two treat-
ments. Therefore, the present protocol describes the
design of an RCT that compares SIRT and TACE as the
first-line therapy for inoperable CCC confined to the liver.
Methods/Design
Trial center and study registration
This is a prospective, single-center, randomized pilot study
with two parallel treatment groups that receive either DEBTACE or SIRT. Stratification will be carried out according
to tumor load (<25% and ≥25%). The study will be per-
formed according to the principles stated in the revised
version of the Declaration of Helsinki. The study has been
approved by the responsible ethics committee (Ethics
Committee of the Medical Chamber of the Federal State
of Rhineland Palatinate, Germany). The reference number
is 837.527.10 (7536).
Participants
The target study population is 24 patients, 12 patients in
each group. If patient numbers in both groups are un-
equal, for example, due to dropouts, recruitment will be
continued until the smaller group includes 12 patients.
Written informed consent will be obtained from each
patient.
Inclusion/exclusion criteria
Inclusion criteria are: age ≥18 years; intrahepatic CCC,
proven by histology or by typical morphology in cross
sectional imaging and elevated tumor markers (CEA or
CA 19–9); tumor confined to the liver; at least one mea-
surable lesion detected on MRI; tumor load ≤50%; pre-
served liver function (Child Pugh A and B).
Exclusion criteria are: patients eligible for curative treat-
ment (resection or local ablation); previous TACE or
SIRT; prior chemotherapy; Child Pugh stage C; Eastern
Cooperative Oncology Group (ECOG) performance
status >1; Tumor involvement >50% of the liver; ex-
trahepatic tumor spread; serum bilirubin >2.0 mg/dl;
serum albumin >2.8 g/dl; serum creatinine >2 mg/dl;
leukocytes <3,000/ml; thrombocytes <50,000/ml; clinically
apparent ascites (ascites only detectable on the CT/MRI is
not considered an exclusion criterion); esophageal blee-
ding during the last 3 months; hepatic encephalopathy;
transjugular intrahepatic portosystemic shunt; any infiltra-
tion or occlusion of the portal vein (including the left,
right, and main branches); hepatofugal blood flow in the
portal vein; hepatopulmonary shunt ≥20% in the macroag-




SIRT is a locoregional treatment that selectively irra-
diates liver tumors. The particles are loaded with the
beta emitter Yttrium 90 (Y-90) and are delivered to the
hepatic artery or its (sub)-segmental branches in order
to embolize and selectively irradiate the tumor. Due to
the short range of beta radiation, the tumor is predo-
minantly targeted, and most of the normal liver tissue is
spared. The procedure is performed once in each liver
lobe. SIRT particles are commercially provided by two
companies, and both are acceptable for a prospective
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one of these products, we will use SirSpheres® in this
study. The most serious complication associated with
SIRT is radiation-induced liver disease, which is, in fact,
radiation-induced liver failure; this condition leads to
death within a few weeks [50,51]. To minimize this com-
plication, the right and left liver lobes will be treated se-
quentially, with a between-treatment interval of 4 weeks.
The liver lobe with the larger tumor mass will be treated
first. The dose for each liver lobe will be calculated ac-
cording to the body surface method [51,52]. This is the
most frequently used approach for resin spheres (73.5%
in a large series of 680 treatments) [53], and it is re-
commended by the manufacturer, SIRTEX, and by the
Radioembolization Brachytherapy Oncology Consortium
(REBOC) [52].
Patients randomized to SIRT will receive a preparative
intervention, including embolization of the collateral ar-
teries (mainly the gastroduodenal artery and the right
gastric artery), and subsequently, an MAA scan will be
performed. Follow-up visits will be performed at 4 and
12 weeks after completion of SIRT treatment, and every
3 months thereafter until the clinical endpoints are
reached. In cases where local tumor progression is de-
tected and no contraindications exist, SIRT can be re-
peated once in each lobe. In cases where contraindications
exist, the patient is allowed to cross over to TACE if there
are no contraindications against TACE.
Control intervention
TACE is a well-established alternative to classic chemo-
therapy in patients with tumors confined to the liver; in
this trial, TACE will serve as the control arm. Numerous
different TACE techniques have been reported in the
literature for treating HCC and CCC [44,47,54]. Since
2006, doxorubicin-loaded DEBs have been commercially
available in various sizes. Compared to conventional
TACE, which uses Lipiodol mixed with a chemothe-
rapeutic agent, DEBs have been shown to be more ef-
fective, with fewer side effects in patients with HCC
[55,56]. Currently, DEB TACE is the only TACE method
that is standardized in terms of the embolization ma-
terial, the chemotherapeutic agent, and the application
technique [55,57]. Because we have considerable expe-
rience with DcBeads®, we will continue to use them ex-
clusively throughout the trial to ensure reproducibility.
The bead size will be 100 to 300 μm.
An optimal dose of 150 mg doxorubicin per appli-
cation was determined in a prospective trial in patients
with HCC [58]; there will be no dose adjustment made
for elevated bilirubin or body surface area. After mixing
with nonionic contrast medium, the DcBeads are to be
administered slowly, and as selectively as possible with a
microcatheter under fluoroscopic control. The mixturewill be infused until the flow is sluggish to avoid reflux.
In cases of incomplete embolization, additional bland
(drug-free) embolization is not permitted. The TACE
procedure will be repeated every 6 weeks as this interval
has been established in several clinical trials for HCC
and intrahepatic CCC [44,47,55,56,59]. TACE treatment
will be carried out until either no viable tumor tissue is
detected by MRI or if any contraindications against
repeated treatment occur (for example relevant ascites,
portal invasion or occlusion of the arterial feeding
vessels). Therefore, additional MRI is indicated prior to
each TACE treatment. After cessation of TACE treat-
ment, follow up will be carried on in 3-month intervals
until the clinical endpoints are reached. In cases where
local tumor progression is detected and no contraindica-
tions exist, TACE can be repeated. In cases where con-
traindications exist, the patient is allowed to cross over
to SIRT if there are no contraindications against SIRT.
Follow-up
Each follow up will include MRI of the liver, a quality-of-
life assessment, documentation of adverse/serious adverse
events, a physical examination, and blood tests. All MRI
examinations will be performed according to a stan-
dardized protocol of MRI sequences, including transversal
T1- and T2-weighted images, diffusion-weighted images,
and multiphasic contrast-enhanced T1-weighted images.
All examinations will be performed on a single 3 T scan-
ner (Skyra®, Siemens Healthcare, Erlangen, Germany).
Outcome measures
PFS is directly related to the local treatment result. The
local tumor response will be measured with the modified
response evaluation criteria in solid tumors (mRECIST)
on the basis of the MRI [60]. In an attempt to eliminate
any potential bias that could derive from the difference
in follow-up intervals, for determination of PFS only the
MRI performed at 3, 6, 9 months et cetera, after the first
treatment will be used in both groups (Figure 1). How-
ever, survival is limited by both tumor progression and
liver performance. Because both treatments also affect
parts of the normal liver parenchyma, they can po-
tentially lead to liver failure. Additionally, extra-hepatic
metastases develop more often in patients with intra-
hepatic CCC than in patients with HCC. Therefore, PFS
will be the primary endpoint, because it includes the
local treatment effect, death by deteriorating liver func-
tion due to liver toxicity, and death due to extra-hepatic
tumor spread.
OS is also influenced by drug-induced impaired liver
function, by extra-hepatic tumor spread, and by secondary
treatment strategies applied after the SIRT/TACE treat-
ment. Therefore, OS is considered a secondary endpoint.
Time to progression (TTP) serves as another secondary
Figure 1 Treatment and follow-up schedule. Follow up begins after the completion of the first treatment. For determination of progression-free
survival (PFS) only the magnetic resonance imaging (MRI) performed at 3, 6, 9 months et cetera, will be used in both groups.
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the basis of the MRI performed at 3, 6, 9 months et cetera,
after the first treatment.
Determination of primary and secondary measures
As indicated above, the local tumor response will be
measured according to the detailed mRECIST criteria on
the basis of the MRIs performed at 3, 6, 9 months et
cetera, after the first treatment [60]. Progression is de-
fined as tumor progression that cannot be properly
treated by the respective local treatment method. The
final decision that progression cannot be treated prop-
erly with the respective local treatment method will be
at the discretion of the investigators after consulting
with an internal tumor conference and the interdis-
ciplinary study team (including members from Surgery,
Hepatology, Oncology, and Nuclear Medicine). Performance
status, evaluated according to the Eastern Cooperative
Oncology Group (ECOG), will be assessed during the
follow-up visits by physical examination.
Quality assurance
To ensure quality execution, patient welfare, and compli-
ance with ethical and legal stipulations, the Interdisciplin-
ary Center for Clinical Trials (IZKS), Mainz, will perform
the regulatory tasks (support in the development and re-
view of study-related documents) and statistical analysis
(carried out by an independent statistician). These func-
tions will be performed according to the standard operat-
ing procedures of IZKS, which are based on the guidelines
stated at the International Conference on Harmonization
of Technical Requirements for the Registration of Phar-
maceuticals for Human Use and good clinical practice.Statistical analysis
The analysis of the study will be performed in a purely
exploratory manner. Statistically significant results are
unlikely unless the difference between the two methods
is greater than expected. The main purpose of the ana-
lysis is to provide estimates of PFS, OS, and TTP. In par-
ticular, the time-to-event data will be analyzed with
Kaplan-Meier methods. Descriptive statistics of all ana-
lyzed parameters will be provided whenever appropriate.Power calculation/analysis
In the absence of previous randomized trials or data re-
garding SIRT as a first-line therapy for patients with
intrahepatic CCC, it is not possible to perform a reliable
power calculation. Therefore, this trial is designed as a
pilot study.Discussion
To the best of our knowledge this will be the first random-
ized trial to compare SIRT and TACE for the treatment of
intra-hepatic CCC. A finding that there are significant dif-
ferences between SIRT and TACE will provide a means to
improve clinical decisions regarding treatment, and it will
directly influence future treatment costs for health insu-
rance companies. The superiority or even non-inferiority
of SIRT would directly impact patient comfort due to
the reduced number of treatment sessions and the pre-
servation of tumor vessel patency for secondary TACE
in cases of potential SIRT failure. If this trial reveals no
significant findings, the results can be used to properly
calculate the number of patients required for a future
confirmatory trial.
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This trial is currently open for recruitment. To date, 12
patients have been included in the study; 6 were random-
ized to the SIRT group and 6 to the TACE group. One pa-
tient in the SIRT group dropped out before treatment
because he developed multiple cholangitic abscesses. To
date, there have been no dropouts in the TACE group.
Because intra-hepatic CCC is a relatively rare tumor,
recruitment is not expected to be completed before Q3
of 2016.
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